Salarius enters $10M equity purchase agreement with C/M Capital Fund

Decoy Therapeutics Inc.

Up to $10M of common stock may be sold over 36 months at 95% of VWAP or closing price.
Purchaser C/M Capital Master Fund obligated to buy when Company directs, subject to conditions.
Exchange Cap of 19.99% of outstanding shares unless stockholder approval or 'at market' exception.
Company to file registration statement within 30 days covering resale of shares.
Proceeds for working capital and general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.